Comparing the effectiveness of bevacizumab to ranibizumab in patients with exudative age-related macular degeneration. The BRAMD study

PLoS ONE

Volumn 11, Issue 5, 2016, Pages

  Schauwvlieghe, A M E ^a   Dijkman, G ^b   Hooymans, J M ^c   Verbraak, F D ^a   Hoyng, C B ^d   Dijkgraaf, M G W ^e   Peto, T ^f   Vingerling, J R ^g   Schlingemann, R O ^a,h  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^c UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^d RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^e ACADEMIC MEDICAL CENTER   (Netherlands)

^f MOORFIELDS EYE HOSPITAL   (United Kingdom)

^g ERASMUS MEDICAL CENTER   (Netherlands)

^h NETHERLANDS INSTITUTE FOR NEUROSCIENCE   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; RANIBIZUMAB;

ADULT; ADVERSE OUTCOME; AGE RELATED MACULAR DEGENERATION; ARTICLE; BENIGN TUMOR; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; DRUG SAFETY; FEMALE; GASTROINTESTINAL DISEASE; HEART DISEASE; HUMAN; INFECTION; MAJOR CLINICAL STUDY; MALE; MALIGNANT NEOPLASTIC DISEASE; NEUROLOGIC DISEASE; RANDOMIZED CONTROLLED TRIAL; SUBRETINAL FLUID; SUBRETINAL NEOVASCULARIZATION; TREATMENT OUTCOME; VISUAL ACUITY; AGED; CLINICAL TRIAL; COMPARATIVE STUDY; DOUBLE BLIND PROCEDURE; MIDDLE AGED; MULTICENTER STUDY; PATHOPHYSIOLOGY; VITREOUS BODY; WET MACULAR DEGENERATION;

AGED; BEVACIZUMAB; DOUBLE-BLIND METHOD; HUMANS; MIDDLE AGED; RANIBIZUMAB; TREATMENT OUTCOME; VISUAL ACUITY; VITREOUS BODY; WET MACULAR DEGENERATION;

EID: 84991518893     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0153052     Document Type: Article

References (18)

1. Schlingemann RO (2004) Role of growth factors and the wound healing response in age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol 242: 91-101. doi: 10.1007/s00417-003-0828-0 PMID: 14685874
2. Vingerling JR, Dielemans I, Hofman A, Grobbee DE, Hijmering M, Kramer CF, et al. (1995) The prevalence of age-related maculopathy in the Rotterdam Study. Ophthalmology 102: 205-210. PMID: 7862408
3. Chakravarthy U, Harding SP, Rogers CA, Downes SM, Lotery AJ, Wordsworth S, et al. (2012) Ranibizumab versus bevacizumab to treat neovascular age-related macular degeneration: one-year findings from the IVAN randomized trial. Ophthalmology 119: 1399-1411. S0161-6420(12)00358-2 [pii]; doi: 10.1016/j.ophtha.2012.04.015 PMID: 22578446
4. Krebs I, Schmetterer L, Boltz A, Told R, Vecsei-Marlovits V, Egger S, et al. (2013) A randomised double-masked trial comparing the visual outcome after treatment with ranibizumab or bevacizumab in patients with neovascular age-related macular degeneration. Br J Ophthalmol 97: 266-271. bjophthalmol-2012-302391 [pii]; doi: 10.1136/bjophthalmol-2012-302391 PMID: 23292928
5. Kodjikian L, Souied EH, Mimoun G, Mauget-Faysse M, Behar-Cohen F, Decullier E, et al. (2013) Ranibizumab versus Bevacizumab for Neovascular Age-related Macular Degeneration: Results from the GEFAL Noninferiority Randomized Trial. Ophthalmology 120: 2300-2309. S0161-6420(13)00524-1 [pii]; doi: 10.1016/j.ophtha.2013.06.020 PMID: 23916488
6. Martin DF, Maguire MG, Ying GS, Grunwald JE, Fine SL, Jaffe GJ (2011) Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med 364: 1897-1908. doi: 10.1056/NEJMoa1102673 PMID: 21526923
7. Chakravarthy U, Harding SP, Rogers CA, Downes SM, Lotery AJ, Culliford LA, et al. (2013) Alternative treatments to inhibit VEGF in age-related choroidal neovascularisation: 2-year findings of the IVAN randomised controlled trial. Lancet 382: 1258-1267. S0140-6736(13)61501-9 [pii]; doi: 10.1016/S0140-6736(13)61501-9 PMID: 23870813
8. Pocock SJ, Simon R (1975) Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial. Biometrics 31: 103-115. PMID: 1100130
9. Kaiser PK, Brown DM, Zhang K, Hudson HL, Holz FG, Shapiro H, et al. (2007) Ranibizumab for predominantly classic neovascular age-related macular degeneration: subgroup analysis of first-year ANCHOR results. Am J Ophthalmol 144: 850-857. S0002-9394(07)00718-0 [pii]; doi: 10.1016/j.ajo.2007.08.012 PMID: 17949673
10. Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK, Chung CY, et al. (2006) Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 355: 1419-1431. 355/14/1419 [pii]; doi: 10.1056/NEJMoa054481 PMID: 17021318
11. Sivaprasad S, Hykin P (2013) What is new in the management of wet age-related macular degeneration? Br Med Bull 105: 201-211. ldt004 [pii]; doi: 10.1093/bmb/ldt004 PMID: 23393060
12. 2002) Bevacizumab. Anti-VEGF monoclonal antibody, avastin, rhumab-VEGF. Drugs R D 3: 28-30. PMID: 11881526
13. Bakri SJ, Snyder MR, Reid JM, Pulido JS, Ezzat MK, Singh RJ (2007) Pharmacokinetics of intravitreal ranibizumab (Lucentis). Ophthalmology 114: 2179-2182. S0161-6420(07)01030-5 [pii]; doi: 10.1016/j.ophtha.2007.09.012 PMID: 18054637
14. Bakri SJ, Snyder MR, Reid JM, Pulido JS, Singh RJ (2007) Pharmacokinetics of intravitreal bevacizumab (Avastin). Ophthalmology 114: 855-859. S0161-6420(07)00083-8 [pii]; doi: 10.1016/j.ophtha.2007.01.017 PMID: 17467524
15. Xu L, Lu T, Tuomi L, Jumbe N, Lu J, Eppler S, et al.(2013) Pharmacokinetics of ranibizumab in patients with neovascular age-related macular degeneration: a population approach. Invest Ophthalmol Vis Sci 54: 1616-1624. iovs.12-10260 [pii]; doi: 10.1167/iovs.12-10260 PMID: 23361508
16. Grunwald JE, Daniel E, Huang J, Ying GS, Maguire MG, Toth CA, Jaffe GJ, et al. (2014) Risk of geographic atrophy in the comparison of age-related macular degeneration treatments trials. Ophthalmology 121: 150-161. S0161-6420(13)00759-8 [pii]; doi: 10.1016/j.ophtha.2013.08.015 PMID: 24084496
17. Martin DF, Maguire MG, Fine SL, Ying GS, Jaffe GJ, Grunwald JE, et al.(2012) Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results. Ophthalmology 119: 1388-1398. S0161-6420(12)00321-1 [pii]; doi: 10.1016/j.ophtha.2012.03.053 PMID: 22555112
18. de KR, de Bruin DM, Verbraak FD, van Leeuwen TG, Faber DJ (2013) Comparison of retinal nerve fiber layer thickness measurements by spectral-domain optical coherence tomography systems using a phantom eye model. J Biophotonics 6: 314-320. doi: 10.1002/jbio.201200018 PMID: 22810965